Expression of programmed death ligand 1 in gastric cancer and its clinical value
WANG Chao1， CHEN Zhi-hong2， WEI Fa-xing3， XU Bin-bin4， ZHU Wei1
(1. School of Medicine, Jiangsu University, Zhenjiang Jiangsu 212013; 2. Department of General Surgery, the Affiliated People′s Hospital of Jiangsu University, Zhenjiang Jiangsu 212002; 3. Department of Emergency, the Affiliated Hospital of Jiangsu University， Zhenjiang Jiangsu 212001； 4. Department of General Surgery, the People′s Hospital of Jintan， Changzhou Jiangsu 213200)
Abstract：Objective: To explore the expression level of programmed death ligand 1(PDL1) in patients with gastric cancer and its clinical value. Methods: The expression of PDL1 was detected by immunohistochemical staining in 76 paraffinembedded tissues and 30 adjacent nontumorous tissues of patients with gastric cancer, and the relationship between the expression of PDL1 and clinicopathological features of gastric cancer patients was analyzed. Results: The positivity rate of PDL1 expression in gastric cancer ［52.6%(40/76)］ was significantly higher than that in adjacent nontumorous tissues［23.3%(7/30),Z=3.104, P=0.002］. The expression of PDL1 in patients with gastric cancer was correlated with differentiation degree(χ2=8.740,P=0.013) and infiltration depth(χ2=8.960,P=0.030), in addition, the expression of PDL1 in gastric cancer with clinical staging of stage Ⅲ+stage Ⅳ was significantly higher than that of stage Ⅰ+stage Ⅱ (χ2=4.133, P=0.042). Conclusion: PDL1 was highly expressed in gastric cancer， which might be considered as a biological indicator for the differentiation and invasion of gastric cancer.
[1\]Dong H, Strome SE, Salomao DR, et al. Tumorassociated B7H1 promotes Tcell apoptosis: a potential mechanism of immune evasion\[J\]. Nat Med, 2002, 8(8): 793-800.\[2\]Thompson RH, Gillett MD, Cheville JC , et al. Costimulatory B7H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target\[J\]. Proc Natl Acad Sci U S A, 2004, 101(49): 17174-17179.\[3\]Konishi J, Yamazaki K, Azuma M, et al. B7H1 expression on nonsmall cell lung cancer cells and its relationship with tumorinfiltrating lymphocytes and their PD1 expression\[J\]. Clin Cancer Res, 2004, 10(15): 5094-5100.\[4\]Ohigashi Y,Sho M,Yamada Y, et al. Clinical significance of programmed death1ligand1 and programmed death1ligand2 expression in human esophageal cancer\[J\]. Clin Cancer Res, 2005, 11(8): 2947-2953.\[5\]Zhang J, Gao J, Nie J, et al. Circulating PDL1 in NSCLC patients and the correlation between the level of PDL1 expression and the clinical characteristics\[J\]. Thorac Cancer, 2015, 6(4): 534-538.\[6\]Bigelow E, Bever KM, Xu H, et al. Immunohistochemical staining of B7H1 (PDL1) on paraffinembedded slides of pancreatic adenocarcinoma tissue\[J\]. J Vis Exp, 2013,(71). pii: 4059.\[7\]Abiko K, Mandai M, Hamanishi J, et al. PDL1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction\[J\]. Clin Cancer Res, 2013, 19(6): 1363-1374.\[8\]Soliman H, Khalil F, Antonia S. PDL1 expression is increased in a subset of basal type breast cancer cells\[J\]. PLoS One, 2014, 9(2): e88557.\[9\]Vlahovic G, Fecci PE, Reardon D, et al. Programmed death ligand 1(PDL1) as an immunotherapy target in patients with glioblastoma\[J\]. Neuro Oncol, 2015, 17(8 ): 1043-1045.\[10\]Zhu H, Qin H, Huang Z, et al. Clinical significance of programmed death ligand1 (PDL1) in colorectal serrated adenocarcinoma\[J\]. Int J Clin Exp Pathol, 2015, 8(8): 9351-9359.\[11\]Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7H1(PDL1) and increase expression after stimulation with IFNγ and TLR ligands via a MyD88, TRAF6, and MEKdependent pathway\[J\]. Blood, 2007, 110(1): 296-304.\[12\]Bajinska J, Viry E, Paggetti J, et al. The critical role of the tumor microenvironment in shaping natural killer cellmediated antitumor immunity\[J\]. Front Immunol，2013，4:490.\[13\]Topalian SL, Drake CG, Pardoll DM. Targeting the PD1/B7H1(PDL1) pathway to activate antitumor immunity\[J\]. Curr Opin Immunol, 2012, 24(2): 207-212.\[14\]韩奕文，徐蓉蔓，陈志红，等.胃癌细胞株及胃癌组织程序性死亡受体1的表达［J］.江苏大学学报（医学版），2016，26（5）：449-451.\[15\]Wang J, Jensen Mi, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains\[J\]. Hum Gene Ther, 2007, 18(8): 712-725.\[16\]Powles T, Eder JP, Fine GD, et al. MPDL3280A (antiPDL1) treatment leads to clinical activity in metastatic bladder cancer\[J\]. Nature, 2014, 515(7528): 558-562.\[17\]Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiPDL1 antibody in patients with advanced cancer\[J\]. N Engl J Med, 2012, 366(26): 2455-2465.
2017, Vol. 27 
